Morepen Laboratories Ltd.

MOREPENLAB

₹51.97

-2.28% (-1.21)

Market Cap

₹2,844 Cr.

P/E

30.72

Key Ratios

Edit Ratio's

Market cap

2,844 Cr

30.72

Prom Holding

35.65 %

ROE (%)

10.21

ROCE (%)

12.80

Div Yield (%)

0.38

Sales

1,781 Cr

OPM (%)

8.23 %

Debt to Equity

0.07

Edit Ratio's

About

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagno… Read more

Low

52W Range

High

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Depreciation Effect

Company is depreciating a greater percentage of assets. this is contributing to a reduction in net profit
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

0 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.07 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

1.58 %

(as of May 19)

Historic

Blood Related - Market Share

0 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.04 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.05 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.02 %

(as of Nov 18)

Historic

Gynecology - Market Share

2 %

(as of Mar 19)

Source/Historic

Loratadine - Market Share in Europe

10 %

(as of Mar 19)

Source/Historic

Loratadine - Market Share in Korea

90 %

(as of Mar 19)

Source/Historic

Loratadine - Market Share in USA

0.01 %

(as of Aug 18)

Historic

Neurological - Market Share

0.01 %

(as of Jun 21)

Historic

Pain - Market Share

0.02 %

(as of Jul 22)

Historic

Pharmaceutical Sector - Market Share

0.04 %

(as of Nov 21)

Historic

Respiratory - Market Share

0 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.01 %

(as of Oct 21)

Historic

Stomatological - Market Share

0.05 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Home Diagnostics / Health

Product Wise Break-Up - Active Pharmaceutical Ingredients (API) & Intermediates

Product Wise Break-Up - Finished Formulations

Location Wise Break-Up

Therapeutic Area Break-Up - Active Pharmaceutical Ingredients (API) & Intermediates

Operational Metrics

Global DMFs filed (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Burnol

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Customers

Novartis India Ltd.

FAQs on Morepen Laboratories Ltd. Business

What does Morepen Laboratories do?

Morepen Laboratories is a pharmaceutical company manufacturing APis, Home Diagnostics, and OTC products. They specialize in anti-allergy drug Loratadine and are prominent in Blood Glucose Monitors and Blood Pressure Monitors domestically.

Who are the competitors of Morepen Laboratories?

Morepen Laboratories major competitors are SMS Pharmaceuticals, Solara Active Pharma, IOL Chem & Pharma, Hester Biosciences, Bajaj Healthcare, Themis Medicare, Aarti Drugs.
Market Cap of Morepen Laboratories is ₹2,917 Crs.
While the median market cap of its peers are ₹2,653 Crs.

Is Morepen Laboratories financially stable compared to its competitors?

Morepen Laboratories seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Monopoly Companies

Companies which are dominant in a product, usually having a strong moat.

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May	Mar Jun Sep	Dec	Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Sep Dec	Sep	Sep	Dec
Investor Presentation	May Aug	Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar May Jun Jul Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Dec
Conference Call	Mar	Mar Jun Sep Dec	Sep Dec	Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar		Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Morepen Laboratories Ltd.

View the discussion on ValuePickr

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Morepen Laboratories Ltd.

Morepen Laboratories Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

11 Yes

2 Neutral

4 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Depreciation Effect

Promoter Holding

Retail Holding

Revenue Recognition

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Current vs Historic Valuation

Debt

Sales Growth

Balance Sheet Strength

Margin Stability

ROCE Strength

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Product Wise Break-Up - Home Diagnostics / Health

UNLOCK PREMIUM

Product Wise Break-Up - Active Pharmaceutical Ingredients (API) & Intermediates

UNLOCK PREMIUM

Product Wise Break-Up - Finished Formulations

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up - Active Pharmaceutical Ingredients (API) & Intermediates

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Brands

Corporate Actions

Customers

FAQs on Morepen Laboratories Ltd. Business

What does Morepen Laboratories do?

Who are the competitors of Morepen Laboratories?

Is Morepen Laboratories financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE